Drug Trial Radar · NCT03762850
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
406
Actual
Start
Dec 11, 2018
Primary completion
Aug 7, 2023
Study completion Aug 19, 2026
Sponsor
- Lead sponsor
- Travere Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 4, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
Conditions
- Immunoglobulin A Nephropathy
Interventions
sparsentanDrug
Target dose of 400 mg daily
irbesartanDrug
Target dose of 300 mg daily
DapagliflozinDrug
Target dose of 10 mg daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in the Urine Protein/Creatinine (UP/C) at Week 36Time frame: Baseline (Day 1) and at Week 36
Locations
162 sites in 18 countries. Site status is shown where the registry gives one.
Travere Investigational Site
Birmingham, Alabama
Travere Investigational Site
Homewood, Alabama
Travere Investigational Site
Glendale, California
Travere Investigational Site
Montebello, California
Travere Investigational Site
Northridge, California
Travere Investigational Site
San Diego, California
Travere Investigational Site
San Diego, California
Travere Investigational Site
Stanford, California
Travere Investigational Site
Denver, Colorado
Travere Investigational Site
Coral Springs, Florida
Travere Investigational Site
Hollywood, Florida
Travere Investigational Site
Miami, Florida
Travere Investigational Site
Miami, Florida
Travere Investigational Site
Winter Park, Florida
Travere Investigational Site
Lawrenceville, Georgia
Travere Investigational Site
Nampa, Idaho
Travere Investigational Site
Hinsdale, Illinois
Travere Investigational Site
Muncie, Indiana
Travere Investigational Site
Kansas City, Kansas
Travere Investigational Site
Louisville, Kentucky
Travere Investigational Site
Boston, Massachusetts
Travere Investigational Site
Springfield, Massachusetts
Travere Investigational Site
Worcester, Massachusetts
Travere Investigational Site
Minneapolis, Minnesota
Travere Investigational Site
Reno, Nevada
Travere Investigational Site
Fresh Meadows, New York
Travere Investigational Site
New York, New York
Travere Investigational Site
Cleveland, Ohio
Travere Investigational Site
Columbus, Ohio
Travere Investigational Site
Philadelphia, Pennsylvania
Travere Investigational Site
Columbia, South Carolina
Travere Investigational Site
El Paso, Texas
Travere Investigational Site
Fort Worth, Texas
Travere Investigational Site
Houston, Texas
Travere Investigational Site
Lewisville, Texas
Travere Investigational Site
San Antonio, Texas
Travere Investigational Site
Salt Lake City, Utah
Travere Investigational Site
Salt Lake City, Utah
Travere Investigational Site
Tacoma, Washington
Travere Investigational Site
Marshfield, Wisconsin
Showing 40 of 162 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.